TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20561878
Drug: Aspirin (88.2%‐85.7%)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (88.2%‐85.7%)
Study: 20561878
Drug: Statins or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statins or cholesterol‐lowering drugs (88.6%‐87%)
Study: 20561878
Drug: Beta-blockers (68%‐55.6%)
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (68%‐55.6%)
Study: 19231245
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg intravenously during anesthetic induction)
Study: 15883757
Drug: Ibutilide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibutilide (1 mg and 1 mg)
Study: 15883757
Drug: Propafenone (70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone (70 mg and 70 mg)
Study: 9618751
Drug: Supraphysiological GH
Normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraphysiological GH treatment (3 IU/m2)
Study: 9618751
Drug: Physiological GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological GH treatment (1 IU/m2 or 2 IU/m2)
Study: 2728827
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil 0.1 mg.kg‐1
Study: 2728827
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (thiamylal 5 mg.kg‐1 and succinylcholine 1.5 mg.kg‐1)
Study: 2728827
Drug: Intravenous verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous verapamil 0.1 mg.kg‐1 (hypertensive patients)
Study: 848533
Drug: Ritodrine in
Normalized name: ritodrine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritodrine in Hartmann's solution
Study: 31060104
Drug: Violet-almond oil
Normalized name: Almond Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Violet-almond oil (intranasal, 2 drops three times a day for one month)
Study: 31060104
Drug: Almond oil
Normalized name: Almond Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Almond oil (intranasal, 2 drops three times a day for one month)
Study: 31060104
Drug: Placebo (1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1% w/v hydroxypropyl methylcellulose solution, intranasal, 2 drops three times a day for one month)
Study: 24672937
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment (Control group)
Study: 12392348
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carbamazepine and lithium
Study: 12392348
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of valproate and olanzapine
Study: 25323541
Drug: Gp‐02 (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gp‐02 (test formulation)
Study: 20303417
Drug: Rabeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole (20 mg, twice daily)
Study: 17403087
Drug: Enoxaparin or
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin or unfractionated heparin
Study: 9780529
Drug: Functional Assessment
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional Assessment of Cancer Therapy instrument
Study: 26039911
Drug: Supragingival therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supragingival therapy group (ST, n = 12) received supragingival scaling
Study: 26039911
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy group (IT, n = 12) underwent supra- and subgingival scaling, as well as root planing
Study: 26039911
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received professional oral hygiene instructions every month
Study: 12626983
Drug: Naloxone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (8 mg four times daily via gastric tube)
Study: 12626983
Drug: Placebo (four
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (four times daily via gastric tube)
Study: 10827889
Drug: Exposure therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure therapy guided by a computer or by a therapist
Study: 9209989
Drug: 0.1 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 cc unpreserved lidocaine 1%
Study: 9209989
Drug: 0.1 cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 cc balanced salt solution (BSS)
Study: 9209989
Drug: 0.5 cc
Normalized name: SureComfort Pen 30g, 0.5 cc, 5/16 inches
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 cc unpreserved lidocaine 1%
Study: 2459788
Drug: Intravesical BCG
Normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical BCG therapy for superficial bladder cancer
Study: 2459788
Drug: Prophylactic antibiotics
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic antibiotics for urinary tract infections
Study: 29424805
Drug: Blonanserin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (8 mg) with alcohol (1 mL/kg)
Study: 29424805
Drug: Blonanserin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blonanserin (8 mg) with water
Study: 19712983
Drug: rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: rosuvastatin 20mg once daily
Study: 12489066
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of voglibose plus a SU compound (glibenclamide or gliclazide)
Study: 12489066
Drug: SU drug
Normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SU drug alone
Study: 9809728
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment (observation group, 46 patients)
Study: 7895348
Drug: Accelerated tissue
Normalized name: tissue respiratory factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated tissue plasminogen activator (TPA) with intravenous heparin
Study: 7895348
Drug: Streptokinase plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptokinase plus TPA with intravenous heparin
Study: 2793316
Drug: No intraocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No intraocular drug (Control)
Study: 330288
Drug: Diclofenac (Voltaren)
Normalized name: diclofenac Topical Gel [Voltaren]
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac (Voltaren) 100 mg twice daily
Study: 6794075
Drug: Doxepin 100
Normalized name: doxepin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxepin 100 mg
Study: 30897095
Drug: Improved infant
Normalized name: Improvest
Approvals — FDA: no, EMA: no, PMDA: no
Description: Improved infant and young child feeding (IYCF) - 20 g of small-quantity lipid-based nutrient supplement per day from age 6 to 18 months plus complementary feeding counseling
Study: 29030692
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection of bevacizumab (IVBe)
Study: 29030692
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal bevacizumab with subtenon triamcinolone injection (IVBe + STTA)
Study: 24981150
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (LD-COC)
Study: 21415280
Drug: Aprepitant (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprepitant (125 mg orally on day 1 and 80 mg orally on each consecutive day through day +4 after HSCT)
Study: 2630378
Drug: self blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: self blood glucose monitoring, twice every other day
Study: 2630378
Drug: self-urine glucose
Normalized name: Urin DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: self-urine glucose monitoring, twice every other day
Study: 798128
Drug: L-dopa +
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa + G 31.406
Study: 798128
Drug: L-dopa +
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa + chl. amantadine
Study: 798128
Drug: L-dopa +
Normalized name: α-methyl-L-dopa
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-dopa + placebo
Study: 30626548
Drug: Bilateral double
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral double suspension sutures (DSS)
Study: 30626548
Drug: Bilateral single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single palatal suspension sutures (SSS)
Study: 28671093
Drug: TCM pulmonary
Normalized name: Lobaria pulmonaria extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCM pulmonary rehabilitation therapy
Study: 21540202
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for fatigue self-management, comprising six weekly 2-hour sessions and a consolidation session at week 14.
Study: 21540202
Drug: Group cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group cognitive behavioural therapy (CBT) for fatigue self-management.
Study: 16718764
Drug: Ecabet sodium
Normalized name: ecabet sodium
DrugBank: Ecabet (DB05265)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ecabet sodium (1.5 g twice a day)
Study: 16718764
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg twice a day)
Study: 17427
Drug: Fazadinium 1
Normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 1 mg/kg
Study: 15467
Drug: Fazadinium 1-25
Normalized name: fazadinium bromide
DrugBank: Fazadinium bromide (DB13745)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fazadinium 1-25 mg/kg
Study: 15467
Drug: Alcuronium 0-32
Normalized name: alcuronium
DrugBank: Alcuronium (DB13648)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcuronium 0-32 mg/kg
Study: 25555887
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 days
Study: 25555887
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 28 days
Study: 25555887
Drug: Buprenorphine/naloxone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone treatment for 4 weeks followed by dose tapering over 7 or 28 days
Study: 21975470
Drug: General postoperation
Approvals — FDA: no, EMA: no, PMDA: no
Description: General postoperation therapy (Group A)
Study: 17873305
Drug: Weekly docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly docetaxel (30 mg/m2), epirubicin (30 mg/m2), and carboplatin (AUC 2) with filgrastim support
Study: 11518846
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment withdrawal (group A1)
Study: 11518846
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment withdrawal (group A2)
Study: 8240556
Drug: Actidose Aqua
Normalized name: ACTIVATED CHARCOAL 208 mg in 1 mL ORAL SUSPENSION [ACTIDOSE AQUA]
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Actidose Aqua AC (1,500 m2/g)
Study: 8240556
Drug: Norit A
Normalized name: Norit A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norit A Supra AC (2,000 m2/g)
Study: 8240556
Drug: Control phase
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control phase (no AC administered)
Study: 29357358
Drug: Psychological intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological intervention programme (cognitive therapy, relaxation therapy, emotional support)
Study: 27624471
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg ferroquine
Study: 23954043
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of health marks and traffic light colour-coding
Study: 14755115
Drug: Formulation I
Normalized name: Recombivax HB, Hepatitis B Vaccine (Recombinant) Pediatric/Adolescent Formulation Injectable Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation I of ramipril (5 mg)
Study: 14755115
Drug: Formulation II
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formulation II of ramipril (5 mg)
Study: 14755115
Drug: Both formulations
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both formulations of ramipril (5 mg)
Study: 10864982
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF at 600 microg and PO dexamethasone at 8 mg
Study: 10864982
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF at 450 microg and PO dexamethasone at 8 mg
Study: 10864982
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF at 450 microg and PO dexamethasone at 12 mg
Study: 10864982
Drug: SC G‐CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC G‐CSF at 450 microg
Study: 10864982
Drug: PO dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PO dexamethasone at 12 mg
Study: 1412655
Drug: Ivermectin (high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (high doses)
Study: 4015937
Drug: Chlormethiazole infusion
Normalized name: chlormethiazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlormethiazole infusion 10 ml min‐1 over 16 (+/‐ 6) min
Study: 4015937
Drug: Diazepam loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam loading dose of 20 (+/‐ 15) mg at a rate of 1 mg min‐1
Study: 30206618
Drug: Plant sterol-enriched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol-enriched beverage (2 g of PS added)
Study: 14668709
Drug: Low-osmolar agents
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-osmolar agents
Study: 10999872
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg and dry powder budesonide 100 microg twice daily
Study: 10999872
Drug: Placebo and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and dry powder budesonide 200 microg twice daily
Study: 8771064
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BTX) injection around one eye
Study: 8771064
Drug: Saline solution
Normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline solution injection around the other eye (Control)
Study: 6366150
Drug: High-dose methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose methotrexate (HDMTX) regimen
Study: 6366150
Drug: Regular follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular follow-up without primary adjuvant chemotherapy
Study: 27129008
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 1%
Study: 27129008
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone gel 2%
Study: 17652452
Drug: Sublingual 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual 400 microg misoprostol and 100 mg diclofenac
Study: 6308996
Drug: Locust bean
Normalized name: Locust Bean Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locust bean gum (LBG) food products (8 to 30 g/day)
Study: 26562708
Drug: Creatine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine (20 g)
Study: 26562708
Drug: Placebo (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (20 g corn starch maltodextrin)
Study: 21733988
Drug: Yoga program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga program (twice a week for 8 weeks)
Study: 17089153
Drug: Carnitine supplementation
Normalized name: carnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carnitine supplementation (CS; n = 7, 4 g day(‐1))
Study: 12215207
Drug: L-carnitine plus
Normalized name: L-Carnitine Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine plus zidovudine (AZT) and didanosine (DDI)
Study: 12215207
Drug: zidovudine (AZT)
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: zidovudine (AZT) and didanosine (DDI) without L-carnitine
Study: 1972375
Drug: Parenteral infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral infusion programs with varying carbohydrate and lipid content (up to 40% of total caloric content)
Study: 1972375
Drug: Lipid solutions
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid solutions used as an energy source in early postoperative period
Study: 31050952
Drug: PBM‐T alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM‐T alone (n = 17), low‐intensity laser (LIL) irradiation (wavelength 660 nm, continuous mode, spot energy 4 J, energy density 142 J/cm2, irradiation time 40 s per spot), once weekly for 4 weeks
Study: 31050952
Drug: PBM‐T+PDT (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBM‐T+PDT (n = 14), combination of PBM‐T and PDT with curcumin as photosensitizer, curcumin solution rinse for 5 min, blue light‐emitting diode irradiation for 5 min, LIL applied as in PBM‐T group
Study: 20027357
Drug: Afala in
Normalized name: DIDECYLDIMONIUM CHLORIDE 2.5 mg in 0.001 L / BENZALKONIUM CHLORIDE 1 mg in 0.001 L TOPICAL GEL [Atala Bio Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Afala in complex treatment
Study: 15117299
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation of treatment by community health workers (CHWs)
Study: 15117299
Drug: Direct observation
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct observation of treatment by family members
Study: 8149522
Drug: Hirulog (direct
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog (direct thrombin inhibitor)
Study: 2970776
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (t‐PA) 150 mg over 8 hours
Study: 2970776
Drug: Intravenous tissue
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tissue plasminogen activator (t‐PA)
Study: 21068351
Drug: High-cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cocoa flavanol (HCF) group (494 mg cocoa flavanols/d)
Study: 21068351
Drug: Low-cocoa flavanol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cocoa flavanol (LCF) group (23 mg cocoa flavanols/d)
Study: 10873356
Drug: Augmentin 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentin 1.2 g (intravenous antibiotic prophylaxis)
Study: 9093048
Drug: Tilt up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tilt up guided treatment
Study: 26321469
Drug: Combined Antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined Antioxidant Therapy (CAT)
Study: 10619581
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ramipril daily for 6 weeks
Study: 23764516
Drug: High-dose, high-repetition
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose, high-repetition medical exercise therapy (MET)
Study: 23764516
Drug: Low-dose, low-repetition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose, low-repetition exercise therapy (Control)
Study: 19523680
Drug: Daily vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily vaginal progesterone gel 90 mg
Study: 17095018
Drug: Arundic acid
Normalized name: Arundic acid
DrugBank: Arundic acid (DB05343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arundic acid (AA) at 8 mg/kg/h
Study: 7654156
Drug: Exposure‐based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exposure‐based treatment without formal cognitive restructuring
Study: 2516883
Drug: Triamterene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triamterene (100 mg orally)
Study: 1105267
Drug: Clonidine at
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine at a daily dose of 150 mug
Study: 31003735
Drug: Once-daily prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily prolonged-release tacrolimus (PRT)
Study: 26094993
Drug: Zonisamide 50
Normalized name: zonisamide 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 50 mg/d
Study: 26094993
Drug: Zonisamide 25
Normalized name: zonisamide 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide 25 mg/d
Study: 21663812
Drug: Remifentanil 0.025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.025 μg/kg/min (Group R25)
Study: 21663812
Drug: Remifentanil 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.05 μg/kg/min (Group R50)
Study: 21663812
Drug: Remifentanil 0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 0.075 μg/kg/min (Group R75)
Study: 7658999
Drug: Exercise-Propranolol test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise-Propranolol test (0.5 mg/kg weight)
Study: 3098950
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium and phosphorus content parenteral nutrition (60-80 mg Ca and 46.5-62 mg P/dl)
Study: 3098950
Drug: Low calcium
Normalized name: Dianeal Low Calcium 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calcium and phosphorus content parenteral nutrition (20 mg Ca and 15.5 mg P/dl)